Bank Of America Corp Seagen Inc. Transaction History

Bank Of America Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $46.7 Million - $51.3 Million	-248,722 Reduced 47.14%	278,847 $53.7 Million
Q1 2023 May 12, 2023	BUY	$127.59 - $203.08 $4.33 Million - $6.89 Million	33,949 Added 6.88%	527,569 $107 Million
Q4 2022 Feb 10, 2023	SELL	$117.37 - $139.17 $1.49 Million - $1.77 Million	-12,702 Reduced 2.51%	493,620 $63.4 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $1.21 Million - $1.61 Million	-8,926 Reduced 1.73%	506,322 $69.3 Million
Q2 2022 Aug 12, 2022	SELL	$108.81 - $179.33 $2.64 Million - $4.35 Million	-24,271 Reduced 4.5%	515,248 $91.2 Million
Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $23.6 Million - $31.2 Million	-197,698 Reduced 26.82%	539,519 $77.7 Million
Q4 2021 Feb 08, 2022	BUY	$142.57 - $190.86 $25.6 Million - $34.3 Million	179,498 Added 32.18%	737,217 $114 Million
Q3 2021 Nov 15, 2021	SELL	$142.45 - $169.82 $848,147 - $1.01 Million	-5,954 Reduced 1.06%	557,719 $94.7 Million
Q2 2021 Sep 13, 2021	BUY	$135.08 - $161.1 $76.1 Million - $90.8 Million	563,673 New	563,673 $89 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.